Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Stroke. 2010 Oct;41(10 Suppl):S129–S134. doi: 10.1161/STROKEAHA.110.595207

CADASIL: EXPERIMENTAL INSIGHTS FROM ANIMAL MODELS

Cenk Ayata 1
PMCID: PMC2953736  NIHMSID: NIHMS237338  PMID: 20876488

Abstract

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) syndrome is the most common monogenic inherited form of small vessel disease, characterized by frequent migraine attacks with aura, recurrent strokes and progressive white matter degeneration. Early vascular cognitive impairment progresses into frank dementia of subcortical type later in life. Linked to mutations in the NOTCH3 gene, CADASIL vasculopathy is associated with accumulation of granular osmiophilic material and NOTCH3 extracellular domain around small caliber arteries and arterioles, and eventual loss of vascular smooth muscle cells. Cerebral blood flow dysregulation has been hypothesized as a major mechanism, largely based on evidence from hemodynamic studies in CADASIL patients. Although animal models expressing CADASIL mutations reproduced the pathology and cerebrovascular dysfunction, the phenotypic spectrum has been quite heterogeneous, possibly due to the choice of genetic constructs and obvious species differences between mouse and man. Nevertheless, these experimental models provide new opportunities to explore the molecular and physiological mechanisms of CADASIL, and address the fundamental question of whether CADASIL phenotype represents loss of NOTCH3 function, or gain of a novel and pathological function. Here, I provide an overview of existing animal models of CADASIL and the pathophysiological insights gained from these models.

Keywords: CADASIL, leukoaraiosis, small vessel disease, vascular cognitive dysfunction

Clinical syndrome

Since its genetic definition in 1990’s, CADASIL syndrome, a prototypical small vessel disease of the brain with Mendelian inheritance, has emerged as an important cause of stroke and pure vascular dementia in young or middle-aged adults13. It is estimated that over 10% of patients with stroke and white matter disease under age 50 may carry a CADASIL mutation4. The clinical syndrome, albeit heterogeneous, is characterized by recurrent lacunar strokes, leukoaraiosis, migraine headaches, mood disturbances and apathy, and dementia. Despite the conspicuous early absence of vascular risk factors such as hypertension, recurrent acute ischemic events start on average within the fifth decade, almost exclusively lacunar infarcts involving subcortical white matter, deep gray matter nuclei and brain stem. Vascular risk factors, when present, can exacerbate disease progression5. The onset of progressive leukoaraiosis precedes lacunar strokes. Indeed, white matter disease is present on neuroimaging in presymptomatic stages, and its penetrance is complete by the end of fourth decade. Cognitive impairment and dementia correlate with the extent of cumulative subcortical pathology, in particular the lacunar infarct burden and brain atrophy6, 7.

Pathology and vascular dysfunction

Besides the lacunar infarcts, diffuse white matter demyelination and axonal loss sparing the subcortical U-fibers, CADASIL brains also display microhemorrhages often in gray matter8 and laminar cortical neuronal apoptosis9, the latter correlating with and possibly secondary to the subcortical lesion load and axonal loss. However, the characteristic histopathological finding in CADASIL is a non-hypertensive, non-atherosclerotic, non-amyloid vasculopathy involving the small-caliber (<500 µm) pial and penetrating arteries and arterioles. The pathognomonic accumulation of granular osmiophilic material10 (GOM) within the tunica media in proximity to the smooth muscle cell membranes is accompanied by degeneration and loss of smooth muscle cells, adventitial fibrosis and mural thickening, and markedly enlarged perivascular spaces11, 12. As a result, luminal stenosis develops in long penetrating arteries supplying subcortical white matter13.

Physiological studies on CADASIL patients have shown an age-dependent reduction in resting cerebral blood flow (CBF), volume and dilatory reserve, and increased oxygen extraction fraction1418. In most studies, hypoperfusion was spatially limited to white matter regions that showed leukoaraiosis, and was comparable to that observed in leukoaraiosis of other etiologies. Endothelial morphological and functional changes have also been noted in systemic vessels1921.

Genetics

CADASIL is caused by mutations in the NOTCH3 gene1, member of an evolutionarily conserved transmembrane receptor family (Drosophila Notch homologues 1–4) regulating context-dependent cell fate determination during metazoan development22. In adult brain, NOTCH3 is expressed almost exclusively by vascular smooth muscle cells (VSMC), preferentially in small caliber arteries, and by pericytes23, 24. NOTCH3 receptor is a heterodimer with a large extracellular segment consisting of 34 tandem epidermal growth factor-like repeats (EGFR) non-covalently attached to a transmembrane domain3. Ligand binding to the extracellular domain activates proteolytic cleavages that shed the extracellular domain and allow translocation of the intracellular segment to the nucleus for transcriptional regulation. Each EGFR contains six conserved cysteine residues. Pathogenic mutations in CADASIL patients identified to date are predominantly missense mutations within the NOTCH3 extracellular domain, and either add or delete cysteine residues resulting in an odd number of cysteines25, 26. This is believed to promote abnormal cysteine-cysteine interactions leading to conformational changes, pathological homo/heterodimerization or multimerization2729. Indeed, in CADASIL, NOTCH3 extracellular domain accumulates in the cytoplasmic membrane of VSMC.

Because of the clinical heterogeneity even among the affected members of a single CADASIL family, it has been difficult to characterize genotype-phenotype associations30, 31. It is possible that the presence of common vascular risk factors or polymorphisms in other genes that modulate NOTCH3 signaling modify the disease progression32. As a potential mechanism for clinical heterogeneity, different CADASIL mutations affect NOTCH3 receptor function and processing in different ways. Some mutations have been shown to interfere with proper receptor handling, at least in vitro (i.e., maturation, trafficking, and clearance)33. Most CADASIL mutations preserve NOTCH3 ligand binding and downstream signal transduction, except those within the ligand binding domain (EGFR 10–11)32, 34, 35. The latter was associated with earlier onset white matter disease and strokes in some families, although, paradoxically, progression of disability and dementia appeared to be slower36, 37. Earlier death or stroke and disability have been linked to other missense mutations as well, and a small in-frame deletion was associated with a phenotype dominated by migraine with severe aura and a paucity of strokes38, 39. Therefore, evidence does suggest distinct genotype-phenotype associations.

Animal models

Several Notch3 mutant mouse models have been developed over the past decade (Table 1). Some reproduced CADASIL-like vasculopathy and white matter disease, and provided important insights into the role of Notch3 in normal vascular structure and function and in CADASIL pathogenesis.

Table 1.

Notch3 mutant mouse models

Mutant transgene Notch3
null41, 43, 44*
R90C human
NOTCH346, 48,
49, 55
R169C
rat
Notch323
C428S
human
NOTCH337
R142C
mouse
Notch347
Promoter knockout Sm22α PAC Sm22α knockin
Genetics Expression level
(% of endogenous Notch3
mRNA)
85% 200–400% 50–150% 100%
Expression distribution arteries arteries, capillaries arteries endogenous pattern
Endogenous Notch3 + or − + + or −
Downstream signaling
GOM and NOTCH3 deposits + + +
Histopathology & ultrastructure VSMC abnormalities (see text for details) + + + +
Capillary density
Cerebral parenchymal pathology +
Resting CBF
Breakthrough hyperemia during hypertensive transients
Upper BP limit of CBF autoregulation
Lower BP limit of CBF autoregulation
Pressure-induced (myogenic) contractions
Cerebrovascular function Flow-mediated (shear stress) dilations
Hypercapnic & acetazolamide-induced hyperemia §
Functional hyperemia (neurovascular coupling)
KCl- and agonist-mediated contractions
Agonist-mediated dilations
Infarct volume and CBF deficit after focal ischemia

Gray shade indicates not studied.

*

Not a CADASIL model;

Heterozygous knockout was indistinguishable from wild type in all aspects;

Normal when expressed on wild type Notch3 background;

§

Normal at 6 mo, but older mice were not tested.

PAC, P1-derived artificial chromosome; GOM, granular osmiophilic material; VSMC, vascular smooth muscle cell; CBF, cerebral blood flow; BP, blood pressure; +, present; −, absent; ↓, diminished; ↑ increased; ↔, unchanged.

Notch3 knockout mice

Although not a genetic model for CADASIL, Notch3 knockout mouse models have nevertheless provided important clues on the role of Notch3 in cerebrovascular homeostasis. Notch3 null mouse models reported to date were viable and fertile, and did not show gross anatomical developmental abnormalities, including the circle of Willis and larger conductance arteries4044. However, ultrastructural studies revealed postnatal VSMC maturation and differentiation defect in small systemic and cerebral resistance arteries of homozygous knockout mice43. Affected arteries displayed enlarged diameters and thinner media resembling veins. Although these ultrastructural abnormalities were not noted in another knockout model41, 45, transcription of genes associated with muscle development and contraction, as well as the canonical Notch downstream targets were nevertheless downregulated in isolated enriched cerebral VSMC41. Functionally, knockout arteries displayed impaired ability to constrict upon increased luminal pressure (i.e., myogenic response) both in vivo and in vitro43, 44, although pharmacological contractions did not differ from the wild type, arguing against a non-specific reduction in contractility41, 44.

Despite these structural and functional defects, Notch3 knockout mice did not develop any parenchymal pathology resembling CADASIL43, but showed increased sensitivity when challenged by induced focal cerebral ischemia41. After transient proximal occlusion the middle cerebral artery using an intraluminal filament, homozygous knockout mice developed significantly larger infarcts compared to wild type. More importantly, conditional transgenic expression of Notch3 in VSMC in the knockout rescued the stroke phenotype41. Implicating a vascular mechanism, Notch3 knockout mice also developed worse CBF deficits upon middle cerebral artery occlusion, suggesting impaired collateral flow (Figure 1). Although these data clearly linked Notch3 signaling to a stroke phenotype, it is not yet clear how impaired myogenic responses in the knockout translate into more severe CBF deficits and larger infarcts upon occlusion of a cerebral artery. Importantly, resting CBF was reportedly normal in Notch3 knockout41, but autoregulatory vasodilation during systemic hypotension was impaired (A. Joutel, unpublished observations), presumably critical for collateral blood supply during acute arterial occlusion.

Figure 1.

Figure 1

Representative laser speckle flowmetry images showing larger area of CBF deficit (blue pixels) in Notch3 knockout (Notch3−/−) mice compared to wild type (Notch3+/+) after distal middle cerebral artery occlusion by a microvascular clip (arrows) through a temporal craniotomy. Blue pixels indicate regions where CBF was below 30% of baseline 60 min after middle cerebral artery occlusion. Imaging field (5×7 mm) was positioned over the right hemisphere as shown in the inset. Along with enlarged infarct volumes in the knockout41, these data link Notch3 signaling to a novel stroke phenotype.

CADASIL mutant mice

To date four mutant mouse models expressing common CADASIL mutations26 (R90C, R169C, C428S, R142C) have been developed and studied in detail. These models differed in their transgenic strategy and expression levels, endogenous Notch3 expression, and the predicted effects of mutations on Notch3 function (Table)23, 37, 46, 47.

Transgenic models variably showed age-dependent ultrastructural abnormalities in cerebral and systemic resistance arteries characteristic for CADASIL, including GOM and NOTCH3 ectodomain deposits; evidence for VSMC degeneration was observed in systemic but not cerebral arteries. At least in the tail arteries, more subtle changes in arterial media including increased actin polymerization and disruption of VSMC anchorage to adjacent cells and matrix appeared to precede the deposits by several months. No vascular pathology was present in transgenic mice overexpressing the wild type NOTCH3. The rate of NOTCH3 deposition in VSMC membranes appeared to be proportional to the expression level of the mutant transgene in different mouse lines. Most notably, in the R169C mutant with highest levels of expression, characteristic NOTCH3 ectodomain aggregates were present as early as 1–2 months of age and GOM deposits around 5 months; both progressively increased with age23. Interestingly, smooth muscle cells otherwise appeared normal in the R169C mutant even at 20 months, setting a contrast with the R90C and C428S transgenic mice. Instead, capillary density was progressively reduced in white but not gray matter starting as early as 5 months, and decreasing to less than 50% of wild type Notch3 transgenic mice at 20 months.

As predicted from the vascular morphological changes, mutant mice showed abnormal vasomotor responses that were in general opposite to the knockout phenotype, with a few exceptions23, 48, 49. For example, R90C transgenic systemic arteries constricted more upon increased luminal pressure, both in vivo and in vitro, and showed impaired ability to dilate in response to a number of physiological stimuli, including hypercapnia, hypotension and functional cortical activation. Interestingly, in the R169C mutant passive dilatory reserve was reduced in the absence of other structural abnormalities such as arterial wall thickness, which may explain the paradoxical attenuation of myogenic tone in this mutant strain. In both R90C and R169C mutants, the onset of vascular dysfunction appeared to precede conspicuous vascular pathology, and in the R90C mutant did not worsen significantly with age, suggesting that vascular dysfunction is not dependent upon GOM and NOTCH3 deposition or degeneration of smooth muscle cells. Importantly, resting CBF was measured in the R169C mutant and found to be reduced, albeit mildly, in both white and gray matter, starting around 12 months and reaching 10–20% reduction at 18 months of age.

Despite the prominent vascular pathology and dysfunction, cerebral parenchymal lesions resembling CADASIL were disappointingly absent in the R90C and C428S mutants. Conspicuous leukoaraiosis did develop in the R169C mutant with the highest level of transgene expression, although lacunar infarcts were still absent23. Senescent R169C mutants (18 months) showed white matter vacuolization, demyelination and astrocytosis involving corpus callosum, internal capsule and other major white matter bundles.

In contrast to the transgenic overexpressors, R142C knockin mice did not develop any anatomical, histopathological or ultrastructural abnormalities, although vasomotor function has not been studied47. This mutation has previously been shown to affect intracellular trafficking but retain Notch3 signaling function, in vitro33. Yet the R142C knockin model showed normal Notch3 receptor expression, cleavage, intracellular trafficking, downstream signaling and ectodomain clearance. The reasons for the lack of CADASIL phenotype in this knockin model are unclear.

Pathophysiological insight from animal models

Available data support chronic cerebrovascular dysfunction and subcortical ischemia punctuated by acute lacunar infarcts as the main disease mechanism in CADASIL. Leukoaraiosis, by virtue of being the earliest sign of CADASIL (i.e., neuroimaging), is the only CADASIL-like parenchymal pathology reproduced in mutant mouse models, and appeared to be, at least by temporal association, secondary to vascular dysfunction and reduced capillary density. However, such a temporal association (i.e., cerebral hypoperfusion preceding leukoaraiosis) has not been unequivocally demonstrated in CADASIL patients. In small clinical series, acetazolamide has been reported to partially restore tissue perfusion50, but whether such drug interventions can impact the progression of subcortical pathology and cognitive dysfunction is not known. Therefore, however plausible, chronic hypoperfusion as the primary cause of leukoaraiosis in CADASIL is far from established. Although Notch3 is exclusively expressed in VSMC and pericytes in adult brain, it is conceivable that CADASIL mutations interfere with normal cellular communication in the neurovascular unit (e.g., between smooth muscle cells and astrocyte end feet), thereby disrupting the homeostasis. NOTCH3 signaling is critical for endothelium-pericyte interactions to promote and maintain microcirculatory networks51, disruption of which may result in microcirculatory rarefaction. The mechanism of lacunar strokes in CADASIL is also not clear. Enhanced myogenic contractility, and mural fibrosis and thickening can conceivably lead to progressive stenosis and occlusions by raising the critical closing pressure of small penetrating arteries. However, significant stenosis does not occur in deep gray matter nuclei where lacunar infarcts also commonly occur in CADASIL patients52, and the degree of luminal stenosis in white matter does not always correlate with the presence of lacunar infarcts53. Ultrastructural and functional abnormalities of endothelial cells have been reported in CADASIL mutant mice and patients, and may play a role in the pathogenesis of lacunar infarcts1921, 46, 54.

Animal models of CADASIL also provide insight into the nature of CADASIL mutations. Although Notch signaling is known to be dosage sensitive, evidence strongly argues against a simple hypomorphic (i.e., loss of function) phenotype in CADASIL. First, Notch3 knockout mice do not develop the characteristic tissue changes observed in CADASIL, and functionally display vasomotor abnormalities that tend to be opposite to those observed in CADASIL mutant mice. Second, majority of CADASIL mutations do not interfere with the membrane trafficking of the receptor or downstream transcriptional signaling. Third, transgenic expression of either functionally active (i.e., R90C and R169C) or inactive (i.e., C428S) mutant NOTCH3 all reproduce the ultrastructural features of CADASIL vasculopathy. Fourth, transgenic expression of the R90C mutant NOTCH3 on a Notch3 knockout background also reproduces GOMs and NOTCH3 aggregates, despite restored downstream signal transduction by the mutant receptor55. Taken together with the autosomal dominant nature of the syndrome, it is unlikely that CADASIL represents a simple loss of function phenotype, although this may be a modulator of the clinical phenotype. Data also do not support a simple hypermorphic phenotype, because CADASIL mutations do not increase downstream NOTCH3 signal transduction55. Interestingly however, an activating NOTCH3 mutation (L1515P in the extracellular heterodimerization domain that does not alter the number of cysteines) which increases NOTCH3 signaling by several fold independent of ligand-binding (i.e., hypermorphic), also causes small vessel disease with early onset lacunar strokes and leukoaraiosis but without GOM or NOTCH3 deposition, hereby distinct from the CADASIL syndrome56. The accumulation of GOMs and mutant NOTCH3 would suggest a neomorphic phenotype (i.e., gain of a novel, pathological function); however, it is not known whether GOM or NOTCH3 aggregates are causally related to vascular dysfunction, leukoaraiosis and lacunar infarcts, or whether they are innocent biomarkers. Animal models also addressed the issue of dominant negative effect (i.e., mutant NOTCH3 antagonizing wild type NOTCH3) with mixed results. Transgenic expression of C428S (loss of function mutation) mutant NOTCH3 on a heterozygous knockout background (i.e., one functional copy of endogenous Notch3, which, alone, is not associated with any structural abnormalities55) inhibited downstream signaling by the normal Notch3 copy when compared to non-transgenic heterozygous knockout37; however, similar experiments using the R90C mutant did not reveal a dominant negative effect55. It should be noted that the level of transgene expression was clearly higher in the C428S mutant compared to the R90C. Overall, the data from mutant mouse models suggest that one or all of these mechanisms may contribute to or modulate the phenotype, possibly explaining some of the clinical heterogeneity in CADASIL.

Commentary

The caveats of extrapolating data from transgenic mice to CADASIL patients notwithstanding (e.g., shorter life span, smaller brain size, overexpression of mutant gene), mutant mouse models have unequivocally shown us that Notch3 is critical for maintaining normal vascular structure and function in adult brain, possibly by acting as a luminal pressure sensor modulating the myogenic response and arterial phenotype of smooth muscle cells43. As summarized above, there has been a fair amount of congruence between clinical and experimental observations. Nevertheless, reproduction of leukoaraiosis and lacunar infarcts in mutant mouse models of CADASIL has been problematic. At best, leukoaraiosis appeared only in one mutant model and very late in its normal life span (18 mo)23, and required significant overexpression of the mutant gene. Moreover, lacunar infarcts, which appear to be a major determinant of disability clinically, have never been reproduced. Yet, leukoaraiosis and lacunar infarcts are the most relevant end points one would like to target pre-clinically for novel therapeutic approaches, since the relevance of GOMs, NOTCH3 aggregates and smooth muscle degeneration for vascular dysfunction, and the relevance of vascular dysfunction for leukoaraiosis and strokes are not yet established. Often in mutant models with subtle but progressive and cumulative abnormalities, phenotypes that otherwise would take a long time to develop can be unveiled by challenging the system. In CADASIL, cerebral vasculature can be experimentally challenged by arterial stenosis or occlusion. This has been tested in the Notch3 knockout mice using an established middle cerebral artery occlusion model, and revealed a novel stroke phenotype in a mutant mouse model which otherwise did not develop parenchymal pathology41. Of course, Notch3 knockout is not a CADASIL model, and similar studies in mice expressing specific CADASIL mutations will undoubtedly add to our understanding of CADASIL and help develop preclinical screening tools for novel therapies. In this regard, established experimental models of stroke and cerebral hypoperfusion are valuable to interrogate the cerebral vasculature and parenchyma in CADASIL mutants, despite the fact that none truly represents lacunar pathophysiology, for which there is, unfortunately, no established experimental model.

Acknowledgments

Acknowledgements and Funding I would like to thank Dr. Anne Joutel for critical feedback on the manuscript. This work was supported in part by grants from NIH (NS061505, NS055104).

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflicts of Interest: None.

References

  • 1.Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, Alamowitch S, Domenga V, Cecillion M, Marechal E, Maciazek J, Vayssiere C, Cruaud C, Cabanis EA, Ruchoux MM, Weissenbach J, Bach JF, Bousser MG, Tournier-Lasserve E. Notch3 mutations in cadasil, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383:707–710. doi: 10.1038/383707a0. [DOI] [PubMed] [Google Scholar]
  • 2.Tournier-Lasserve E, Joutel A, Melki J, Weissenbach J, Lathrop GM, Chabriat H, Mas JL, Cabanis EA, Baudrimont M, Maciazek J, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat Genet. 1993;3:256–259. doi: 10.1038/ng0393-256. [DOI] [PubMed] [Google Scholar]
  • 3.Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil. Lancet Neurol. 2009;8:643–653. doi: 10.1016/S1474-4422(09)70127-9. [DOI] [PubMed] [Google Scholar]
  • 4.Dong Y, Hassan A, Zhang Z, Huber D, Dalageorgou C, Markus HS. Yield of screening for cadasil mutations in lacunar stroke and leukoaraiosis. Stroke. 2003;34:203–205. doi: 10.1161/01.str.0000048162.16852.88. [DOI] [PubMed] [Google Scholar]
  • 5.Adib-Samii P, Brice G, Martin RJ, Markus HS. Clinical spectrum of cadasil and the effect of cardiovascular risk factors on phenotype: Study in 200 consecutively recruited individuals. Stroke. 41:630–634. doi: 10.1161/STROKEAHA.109.568402. [DOI] [PubMed] [Google Scholar]
  • 6.Viswanathan A, Gschwendtner A, Guichard JP, Buffon F, Cumurciuc R, O'Sullivan M, Holtmannspotter M, Pachai C, Bousser MG, Dichgans M, Chabriat H. Lacunar lesions are independently associated with disability and cognitive impairment in cadasil. Neurology. 2007;69:172–179. doi: 10.1212/01.wnl.0000265221.05610.70. [DOI] [PubMed] [Google Scholar]
  • 7.Liem MK, van der Grond J, Haan J, van den Boom R, Ferrari MD, Knaap YM, Breuning MH, van Buchem MA, Middelkoop HA, Lesnik Oberstein SA. Lacunar infarcts are the main correlate with cognitive dysfunction in cadasil. Stroke. 2007;38:923–928. doi: 10.1161/01.STR.0000257968.24015.bf. [DOI] [PubMed] [Google Scholar]
  • 8.Lesnik Oberstein SA, van den Boom R, van Buchem MA, van Houwelingen HC, Bakker E, Vollebregt E, Ferrari MD, Breuning MH, Haan J. Cerebral microbleeds in cadasil. Neurology. 2001;57:1066–1070. doi: 10.1212/wnl.57.6.1066. [DOI] [PubMed] [Google Scholar]
  • 9.Viswanathan A, Gray F, Bousser MG, Baudrimont M, Chabriat H. Cortical neuronal apoptosis in cadasil. Stroke. 2006;37:2690–2695. doi: 10.1161/01.STR.0000245091.28429.6a. [DOI] [PubMed] [Google Scholar]
  • 10.Tikka S, Mykkanen K, Ruchoux MM, Bergholm R, Junna M, Poyhonen M, Yki-Jarvinen H, Joutel A, Viitanen M, Baumann M, Kalimo H. Congruence between notch3 mutations and gom in 131 cadasil patients. Brain. 2009;132:933–939. doi: 10.1093/brain/awn364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Okeda R, Arima K, Kawai M. Arterial changes in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (cadasil) in relation to pathogenesis of diffuse myelin loss of cerebral white matter: Examination of cerebral medullary arteries by reconstruction of serial sections of an autopsy case. Stroke. 2002;33:2565–2569. doi: 10.1161/01.str.0000032620.91848.1c. [DOI] [PubMed] [Google Scholar]
  • 12.Yamamoto Y, Ihara M, Tham C, Low RW, Slade JY, Moss T, Oakley AE, Polvikoski T, Kalaria RN. Neuropathological correlates of temporal pole white matter hyperintensities in cadasil. Stroke. 2009;40:2004–2011. doi: 10.1161/STROKEAHA.108.528299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Miao Q, Paloneva T, Tuominen S, Poyhonen M, Tuisku S, Viitanen M, Kalimo H. Fibrosis and stenosis of the long penetrating cerebral arteries: The cause of the white matter pathology in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Brain Pathol. 2004;14:358–364. doi: 10.1111/j.1750-3639.2004.tb00078.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Bruening R, Dichgans M, Berchtenbreiter C, Yousry T, Seelos KC, Wu RH, Mayer M, Brix G, Reiser M. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: Decrease in regional cerebral blood volume in hyperintense subcortical lesions inversely correlates with disability and cognitive performance. AJNR Am J Neuroradiol. 2001;22:1268–1274. [PMC free article] [PubMed] [Google Scholar]
  • 15.Chabriat H, Pappata S, Ostergaard L, Clark CA, Pachot-Clouard M, Vahedi K, Jobert A, Le Bihan D, Bousser MG. Cerebral hemodynamics in cadasil before and after acetazolamide challenge assessed with mri bolus tracking. Stroke. 2000;31:1904–1912. doi: 10.1161/01.str.31.8.1904. [DOI] [PubMed] [Google Scholar]
  • 16.Pfefferkorn T, von Stuckrad-Barre S, Herzog J, Gasser T, Hamann GF, Dichgans M. Reduced cerebrovascular co(2) reactivity in cadasil: A transcranial doppler sonography study. Stroke. 2001;32:17–21. doi: 10.1161/01.str.32.1.17. [DOI] [PubMed] [Google Scholar]
  • 17.van den Boom R, Lesnik Oberstein SA, Spilt A, Behloul F, Ferrari MD, Haan J, Westendorp RG, van Buchem MA. Cerebral hemodynamics and white matter hyperintensities in cadasil. J Cereb Blood Flow Metab. 2003;23:599–604. doi: 10.1097/01.WCB.0000062341.61367.D3. [DOI] [PubMed] [Google Scholar]
  • 18.Tuominen S, Miao Q, Kurki T, Tuisku S, Poyhonen M, Kalimo H, Viitanen M, Sipila HT, Bergman J, Rinne JO. Positron emission tomography examination of cerebral blood flow and glucose metabolism in young cadasil patients. Stroke. 2004;35:1063–1067. doi: 10.1161/01.STR.0000124124.69842.2d. [DOI] [PubMed] [Google Scholar]
  • 19.Peters N, Freilinger T, Opherk C, Pfefferkorn T, Dichgans M. Enhanced l-arginine-induced vasoreactivity suggests endothelial dysfunction in cadasil. J Neurol. 2008;255:1203–1208. doi: 10.1007/s00415-008-0876-9. [DOI] [PubMed] [Google Scholar]
  • 20.Stenborg A, Kalimo H, Viitanen M, Terent A, Lind L. Impaired endothelial function of forearm resistance arteries in cadasil patients. Stroke. 2007;38:2692–2697. doi: 10.1161/STROKEAHA.107.490029. [DOI] [PubMed] [Google Scholar]
  • 21.Ruchoux MM, Maurage CA. Endothelial changes in muscle and skin biopsies in patients with cadasil. Neuropathol Appl Neurobiol. 1998;24:60–65. doi: 10.1046/j.1365-2990.1998.00087.x. [DOI] [PubMed] [Google Scholar]
  • 22.Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: Cell fate control and signal integration in development. Science. 1999;284:770–776. doi: 10.1126/science.284.5415.770. [DOI] [PubMed] [Google Scholar]
  • 23.Joutel A, Monet-Lepretre M, Gosele C, Baron-Menguy C, Hammes A, Schmidt S, Lemaire-Carrette B, Domenga V, Schedl A, Lacombe P, Hubner N. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J Clin Invest. 120:433–445. doi: 10.1172/JCI39733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Joutel A, Andreux F, Gaulis S, Domenga V, Cecillon M, Battail N, Piga N, Chapon F, Godfrain C, Tournier-Lasserve E. The ectodomain of the notch3 receptor accumulates within the cerebrovasculature of cadasil patients. J Clin Invest. 2000;105:597–605. doi: 10.1172/JCI8047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Peters N, Opherk C, Bergmann T, Castro M, Herzog J, Dichgans M. Spectrum of mutations in biopsy-proven cadasil: Implications for diagnostic strategies. Arch Neurol. 2005;62:1091–1094. doi: 10.1001/archneur.62.7.1091. [DOI] [PubMed] [Google Scholar]
  • 26.Joutel A, Vahedi K, Corpechot C, Troesch A, Chabriat H, Vayssiere C, Cruaud C, Maciazek J, Weissenbach J, Bousser MG, Bach JF, Tournier-Lasserve E. Strong clustering and stereotyped nature of notch3 mutations in cadasil patients. Lancet. 1997;350:1511–1515. doi: 10.1016/S0140-6736(97)08083-5. [DOI] [PubMed] [Google Scholar]
  • 27.Dichgans M, Ludwig H, Muller-Hocker J, Messerschmidt A, Gasser T. Small in-frame deletions and missense mutations in cadasil: 3d models predict misfolding of notch3 egf-like repeat domains. Eur J Hum Genet. 2000;8:280–285. doi: 10.1038/sj.ejhg.5200460. [DOI] [PubMed] [Google Scholar]
  • 28.Donahue CP, Kosik KS. Distribution pattern of notch3 mutations suggests a gain-of-function mechanism for cadasil. Genomics. 2004;83:59–65. doi: 10.1016/s0888-7543(03)00206-4. [DOI] [PubMed] [Google Scholar]
  • 29.Opherk C, Duering M, Peters N, Karpinska A, Rosner S, Schneider E, Bader B, Giese A, Dichgans M. Cadasil mutations enhance spontaneous multimerization of notch3. Hum Mol Genet. 2009;18:2761–2767. doi: 10.1093/hmg/ddp211. [DOI] [PubMed] [Google Scholar]
  • 30.Dichgans M, Filippi M, Bruning R, Iannucci G, Berchtenbreiter C, Minicucci L, Uttner I, Crispin A, Ludwig H, Gasser T, Yousry TA. Quantitative mri in cadasil: Correlation with disability and cognitive performance. Neurology. 1999;52:1361–1367. doi: 10.1212/wnl.52.7.1361. [DOI] [PubMed] [Google Scholar]
  • 31.Dichgans M, Mayer M, Uttner I, Bruning R, Muller-Hocker J, Rungger G, Ebke M, Klockgether T, Gasser T. The phenotypic spectrum of cadasil: Clinical findings in 102 cases. Ann Neurol. 1998;44:731–739. doi: 10.1002/ana.410440506. [DOI] [PubMed] [Google Scholar]
  • 32.Singhal S, Bevan S, Barrick T, Rich P, Markus HS. The influence of genetic and cardiovascular risk factors on the cadasil phenotype. Brain. 2004;127:2031–2038. doi: 10.1093/brain/awh223. [DOI] [PubMed] [Google Scholar]
  • 33.Karlstrom H, Beatus P, Dannaeus K, Chapman G, Lendahl U, Lundkvist J. A cadasil-mutated notch 3 receptor exhibits impaired intracellular trafficking and maturation but normal ligand-induced signaling. Proc Natl Acad Sci U S A. 2002;99:17119–17124. doi: 10.1073/pnas.252624099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Peters N, Opherk C, Zacherle S, Capell A, Gempel P, Dichgans M. Cadasil-associated notch3 mutations have differential effects both on ligand binding and ligand-induced notch3 receptor signaling through rbp-jk. Exp Cell Res. 2004;299:454–464. doi: 10.1016/j.yexcr.2004.06.004. [DOI] [PubMed] [Google Scholar]
  • 35.Joutel A, Monet M, Domenga V, Riant F, Tournier-Lasserve E. Pathogenic mutations associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect jagged1 binding and notch3 activity via the rbp/jk signaling pathway. Am J Hum Genet. 2004;74:338–347. doi: 10.1086/381506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Arboleda-Velasquez JF, Lopera F, Lopez E, Frosch MP, Sepulveda-Falla D, Gutierrez JE, Vargas S, Medina M, Martinez De Arrieta C, Lebo RV, Slaugenhaupt SA, Betensky RA, Villegas A, Arcos-Burgos M, Rivera D, Restrepo JC, Kosik KS. C455r notch3 mutation in a colombian cadasil kindred with early onset of stroke. Neurology. 2002;59:277–279. doi: 10.1212/wnl.59.2.277. [DOI] [PubMed] [Google Scholar]
  • 37.Monet-Lepretre M, Bardot B, Lemaire B, Domenga V, Godin O, Dichgans M, Tournier-Lasserve E, Cohen-Tannoudji M, Chabriat H, Joutel A. Distinct phenotypic and functional features of cadasil mutations in the notch3 ligand binding domain. Brain. 2009;132:1601–1612. doi: 10.1093/brain/awp049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Joutel A, Chabriat H, Vahedi K, Domenga V, Vayssiere C, Ruchoux MM, Lucas C, Leys D, Bousser MG, Tournier-Lasserve E. Splice site mutation causing a seven amino acid notch3 in-frame deletion in cadasil. Neurology. 2000;54:1874–1875. doi: 10.1212/wnl.54.9.1874. [DOI] [PubMed] [Google Scholar]
  • 39.Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M. Long-term prognosis and causes of death in cadasil: A retrospective study in 411 patients. Brain. 2004;127:2533–2539. doi: 10.1093/brain/awh282. [DOI] [PubMed] [Google Scholar]
  • 40.Krebs LT, Xue Y, Norton CR, Sundberg JP, Beatus P, Lendahl U, Joutel A, Gridley T. Characterization of notch3-deficient mice: Normal embryonic development and absence of genetic interactions with a notch1 mutation. Genesis. 2003;37:139–143. doi: 10.1002/gene.10241. [DOI] [PubMed] [Google Scholar]
  • 41.Arboleda-Velasquez JF, Zhou Z, Shin HK, Louvi A, Kim HH, Savitz SI, Liao JK, Salomone S, Ayata C, Moskowitz MA, Artavanis-Tsakonas S. Linking notch signaling to ischemic stroke. Proc Natl Acad Sci U S A. 2008;105:4856–4861. doi: 10.1073/pnas.0709867105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Kitamoto T, Takahashi K, Takimoto H, Tomizuka K, Hayasaka M, Tabira T, Hanaoka K. Functional redundancy of the notch gene family during mouse embryogenesis: Analysis of notch gene expression in notch3-deficient mice. Biochem Biophys Res Commun. 2005;331:1154–1162. doi: 10.1016/j.bbrc.2005.03.241. [DOI] [PubMed] [Google Scholar]
  • 43.Domenga V, Fardoux P, Lacombe P, Monet M, Maciazek J, Krebs LT, Klonjkowski B, Berrou E, Mericskay M, Li Z, Tournier-Lasserve E, Gridley T, Joutel A. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev. 2004;18:2730–2735. doi: 10.1101/gad.308904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Belin de Chantemele EJ, Retailleau K, Pinaud F, Vessieres E, Bocquet A, Guihot AL, Lemaire B, Domenga V, Baufreton C, Loufrani L, Joutel A, Henrion D. Notch3 is a major regulator of vascular tone in cerebral and tail resistance arteries. Arterioscler Thromb Vasc Biol. 2008;28:2216–2224. doi: 10.1161/ATVBAHA.108.171751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Mitchell KJ, Pinson KI, Kelly OG, Brennan J, Zupicich J, Scherz P, Leighton PA, Goodrich LV, Lu X, Avery BJ, Tate P, Dill K, Pangilinan E, Wakenight P, Tessier-Lavigne M, Skarnes WC. Functional analysis of secreted and transmembrane proteins critical to mouse development. Nat Genet. 2001;28:241–249. doi: 10.1038/90074. [DOI] [PubMed] [Google Scholar]
  • 46.Ruchoux MM, Domenga V, Brulin P, Maciazek J, Limol S, Tournier-Lasserve E, Joutel A. Transgenic mice expressing mutant notch3 develop vascular alterations characteristic of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Am J Pathol. 2003;162:329–342. doi: 10.1016/S0002-9440(10)63824-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Lundkvist J, Zhu S, Hansson EM, Schweinhardt P, Miao Q, Beatus P, Dannaeus K, Karlstrom H, Johansson CB, Viitanen M, Rozell B, Spenger C, Mohammed A, Kalimo H, Lendahl U. Mice carrying a r142c notch 3 knock-in mutation do not develop a cadasil-like phenotype. Genesis. 2005;41:13–22. doi: 10.1002/gene.20091. [DOI] [PubMed] [Google Scholar]
  • 48.Dubroca C, Lacombe P, Domenga V, Maciazek J, Levy B, Tournier-Lasserve E, Joutel A, Henrion D. Impaired vascular mechanotransduction in a transgenic mouse model of cadasil arteriopathy. Stroke. 2005;36:113–117. doi: 10.1161/01.STR.0000149949.92854.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Lacombe P, Oligo C, Domenga V, Tournier-Lasserve E, Joutel A. Impaired cerebral vasoreactivity in a transgenic mouse model of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy arteriopathy. Stroke. 2005;36:1053–1058. doi: 10.1161/01.STR.0000163080.82766.eb. [DOI] [PubMed] [Google Scholar]
  • 50.Huang L, Yang Q, Zhang L, Chen X, Huang Q, Wang H. Acetazolamide improves cerebral hemodynamics in cadasil. J Neurol Sci. 292:77–80. doi: 10.1016/j.jns.2010.01.023. [DOI] [PubMed] [Google Scholar]
  • 51.Liu H, Kennard S, Lilly B. Notch3 expression is induced in mural cells through an autoregulatory loop that requires endothelial-expressed jagged1. Circ Res. 2009;104:466–475. doi: 10.1161/CIRCRESAHA.108.184846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Miao Q, Paloneva T, Tuisku S, Roine S, Poyhonen M, Viitanen M, Kalimo H. Arterioles of the lenticular nucleus in cadasil. Stroke. 2006;37:2242–2247. doi: 10.1161/01.STR.0000236838.84150.c2. [DOI] [PubMed] [Google Scholar]
  • 53.Miao Q, Kalimo H, Bogdanovic N, Kostulas K, Borjesson-Hanson A, Viitanen M. Cerebral arteriolar pathology in a 32-year-old patient with cadasil. Neuropathol Appl Neurobiol. 2006;32:455–458. doi: 10.1111/j.1365-2990.2006.00746.x. [DOI] [PubMed] [Google Scholar]
  • 54.Rufa A, Blardi P, De Lalla A, Cevenini G, De Stefano N, Zicari E, Auteri A, Federico A, Dotti MT. Plasma levels of asymmetric dimethylarginine in cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy. Cerebrovasc Dis. 2008;26:636–640. doi: 10.1159/000166840. [DOI] [PubMed] [Google Scholar]
  • 55.Monet M, Domenga V, Lemaire B, Souilhol C, Langa F, Babinet C, Gridley T, Tournier-Lasserve E, Cohen-Tannoudji M, Joutel A. The archetypal r90c cadasil-notch3 mutation retains notch3 function in vivo. Hum Mol Genet. 2007 doi: 10.1093/hmg/ddm042. [DOI] [PubMed] [Google Scholar]
  • 56.Fouillade C, Chabriat H, Riant F, Mine M, Arnoud M, Magy L, Bousser MG, Tournier-Lasserve E, Joutel A. Activating notch3 mutation in a patient with small-vessel-disease of the brain. Hum Mutat. 2008;29:452. doi: 10.1002/humu.9527. [DOI] [PubMed] [Google Scholar]

RESOURCES